Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Berchem – page 45

2 112 clinical trials in Berchem, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Berchem at a glance
2 112
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 112 trials in Berchem

Open in trial search

Study of Volrustomig and Drug Combination for Patients with Early-stage Resectable Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study on Tabelecleucel for Patients with Epstein-Barr Virus-Associated Diseases

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tabelecleucel
  • Sponsor:Pierre Fabre Medicament

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Study on the Effectiveness of INM004 for Children with Hemolytic Uremic Syndrome Caused by Shiga Toxin-Producing E. coli

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:EQUINE SHIGA TOXIN 1/2 IMMUNE FAB2
  • Sponsor:Chemo Research S.L.

Study on the Safety and Effects of Givinostat in Young Children with Duchenne Muscular Dystrophy (Ages 2 to Less Than 6 Years)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Givinostat
  • Sponsor:Italfarmaco S.p.A.

Long-Term Safety and Efficacy Study of Mexiletine Hydrochloride for Patients with Myotonic Dystrophy Type 1 and Type 2

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mexiletine Hydrochloride
  • Sponsor:Lupin Atlantis Holdings S.A.

Study on VE303 for Preventing Recurrent C. difficile Infection in Patients

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bacilli, Cluster Xvii, Strain Relative Clostridium_Aq Innocuum, Live
  • Sponsor:Vedanta Biosciences Inc.

Study of Avapritinib for Adults with Systemic Mastocytosis Who Previously Participated in an Avapritinib Study

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Avapritinib
  • Sponsor:Blueprint Medicines Corp.

Study of Ruxolitinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with IL-7R/JAK-STAT Pathway Mutations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Ruxolitinib
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Study of Brigatinib for Children and Young Adults with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, or Other Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Brigatinib
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Neoplasm+1

Recruiting

Study of NVL-655 for Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with ALK Mutation

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:NVL-655
  • Sponsor:Nuvalent Inc.

Study on Preventing Hepatic Encephalopathy with Rifaximin and Lactulose in Patients with Alcoholic Liver Cirrhosis Undergoing TIPS Placement

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Lactulose
  • Sponsor:Amsterdam UMC Stichting

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Berchem

What the registry says about research in the country

01 Gastrointestinal Research

Clinical trials focusing on optimizing treatment strategies for patients with functional dyspepsia and related conditions like heartburn and reflux.

  • PPI De-prescribing Strategies
  • Alternative Treatment Approaches
  • Long-term Medication Management

Research evaluates various approaches to reducing proton pump inhibitor usage, including on-demand therapy and alternative treatments with alginate formulations.

02 Primary Care Innovation

Studies examining the effectiveness of different medication reduction strategies in the primary care setting, with a focus on improving patient outcomes.

  • Medication Optimization
  • Patient-Centered Care
  • Treatment Sustainability

The research aims to establish evidence-based protocols for discontinuing long-term medications when they may no longer be clinically indicated.

03 Therapeutic Management

Investigation of comparative effectiveness between different therapeutic approaches for chronic gastrointestinal conditions.

  • Treatment Comparison Studies
  • Clinical Outcomes Assessment
  • Quality of Life Impact

Research focuses on determining optimal strategies for transitioning patients from long-term medication use to alternative management approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.